Modification of 10b5-1 Plan by Robert C. Goeltz II of Arcus Biosciences, Inc.

Robert C. Goeltz II, an officer of Arcus Biosciences, Inc., has modified his 10b5-1 trading plan on February 23, 2024. The plan involves the sale of 5,000 common shares of Arcus Biosciences, Inc., which were acquired on December 15, 2023, through equity compensation. The shares are scheduled to be sold on October 28, 2025, with an aggregate market value of $100,000. The transaction will be facilitated by Merrill Lynch. The filing also confirms that there have been no securities sold in the past three months.